Therapeutic Area | MeSH |
---|---|
infections | D007239 |
skin and connective tissue diseases | D017437 |
Brand Name | Status | Last Update |
---|---|---|
dalbavancin | New Drug Application | 2014-06-05 |
dalvance | New Drug Application | 2021-07-28 |
Expiration | Code | ||
---|---|---|---|
DALBAVANCIN HYDROCHLORIDE, DALVANCE, ABBVIE | |||
2024-07-22 | NPP | ||
2024-05-23 | GAIN | ||
2019-05-23 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Dalbavancin Hydrochloride, Dalvance, Abbvie | |||
6900175 | 2028-05-23 | U-3499 |
Code | Description |
---|---|
J0875 | Injection, dalbavancin, 5 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 79 | 2 | 1 | 2 | 15 | 97 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 30 | 39 | 8 | 1 | 14 | 80 |
Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 6 | 7 | 2 | 36 | 55 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 10 | 7 | 7 | 12 | 19 | 51 |
Covid-19 | D000086382 | — | U07.1 | 7 | 16 | 11 | 2 | 12 | 39 |
Prostatic neoplasms | D011471 | — | C61 | 11 | 16 | 9 | 1 | 7 | 39 |
Heart failure | D006333 | HP_0001635 | I50 | 2 | 11 | 6 | 2 | 13 | 33 |
Hiv infections | D015658 | EFO_0000764 | B20 | 17 | 4 | 2 | 1 | 7 | 30 |
Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | 2 | 9 | 9 | 8 | 30 |
Pain | D010146 | EFO_0003843 | R52 | 1 | 4 | 9 | 3 | 12 | 29 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 91 | 43 | 7 | — | 19 | 131 |
Non-small-cell lung carcinoma | D002289 | — | — | 29 | 42 | 6 | — | 3 | 63 |
Colorectal neoplasms | D015179 | — | — | 13 | 22 | 6 | — | 10 | 41 |
Myeloid leukemia acute | D015470 | — | C92.0 | 17 | 23 | 5 | — | 2 | 36 |
Melanoma | D008545 | — | — | 19 | 20 | 1 | — | 4 | 35 |
Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 3 | 3 | — | 29 | 35 |
Multiple myeloma | D009101 | — | C90.0 | 10 | 13 | 4 | — | 4 | 27 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 9 | 12 | 5 | — | 3 | 25 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 7 | 14 | 5 | — | 1 | 24 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 11 | 11 | 4 | — | — | 21 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 8 | 4 | — | — | 5 | 14 |
Head and neck neoplasms | D006258 | — | — | 5 | 7 | — | — | 2 | 13 |
Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 2 | — | — | 11 | 13 |
Glioblastoma | D005909 | EFO_0000515 | — | 5 | 9 | — | — | — | 12 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 6 | — | — | 2 | 10 |
Small cell lung carcinoma | D055752 | — | — | 6 | 6 | — | — | 1 | 9 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 4 | 4 | — | — | 1 | 8 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 5 | 6 | — | — | — | 8 |
Pruritus | D011537 | HP_0000989 | L29 | — | 1 | — | — | 7 | 8 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 3 | 2 | — | — | 3 | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pulmonary arterial hypertension | D000081029 | — | — | 3 | — | — | — | 3 | 6 |
Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | — | — | — | 3 | 4 |
Falciparum malaria | D016778 | EFO_0007444 | B50 | 3 | — | — | — | — | 3 |
Neuroblastoma | D009447 | EFO_0000621 | — | 3 | — | — | — | — | 3 |
Mesothelioma | D008654 | — | C45 | 2 | — | — | — | 1 | 3 |
Pulmonary fibrosis | D011658 | — | J84.10 | 2 | — | — | — | 1 | 3 |
Dental pulp necrosis | D003790 | — | K04.1 | 3 | — | — | — | — | 3 |
Ebolavirus | D029043 | — | — | 3 | — | — | — | — | 3 |
Professional burnout | D002055 | — | — | 1 | — | — | — | 2 | 3 |
Ependymoma | D004806 | — | — | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 16 | 16 |
Sleep | D012890 | GO_0030431 | — | — | — | — | — | 7 | 7 |
Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | — | 7 | 7 |
Cerebral palsy | D002547 | — | G80 | — | — | — | — | 6 | 6 |
Insulin resistance | D007333 | HP_0000855 | E88.819 | — | — | — | — | 5 | 5 |
Sedentary behavior | D057185 | — | — | — | — | — | — | 5 | 5 |
Trigger finger disorder | D052582 | — | M65.3 | — | — | — | — | 5 | 5 |
Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 5 | 5 |
Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | — | — | — | 5 | 5 |
Shoulder pain | D020069 | HP_0030834 | M25.51 | — | — | — | — | 5 | 5 |
Drug common name | Dalbavancin |
INN | dalbavancin |
Description | Dalbavancin is a semisynthetic glycopeptide used for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA. It has a role as an antibacterial drug and an antimicrobial agent. It is a carbohydrate acid derivative, a monosaccharide derivative, a glycopeptide and a semisynthetic derivative. |
Classification | Small molecule |
Drug class | vancomycin-related compounds |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O |
PDB | — |
CAS-ID | 171500-79-1 |
RxCUI | — |
ChEMBL ID | CHEMBL3301669 |
ChEBI ID | 82721 |
PubChem CID | 16134627 |
DrugBank | DB06219 |
UNII ID | 808UI9MS5K (ChemIDplus, GSRS) |